Additional file 1: of Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma

  • Noah Berlow (Creator)
  • Rishi Rikhi (Contributor)
  • Mathew Geltzeiler (Creator)
  • Jinu Abraham (Contributor)
  • Matthew N. Svalina (Creator)
  • Lara E. Davis (Creator)
  • Erin Wise (Creator)
  • Maria Mancini (Creator)
  • Jonathan Noujaim (Creator)
  • Atiya Mansoor (Contributor)
  • Michael J. Quist (Creator)
  • Kevin L. Matlock (Creator)
  • Martin W. Goros (Creator)
  • Brian S. Hernandez (Creator)
  • Yee C. Doung (Creator)
  • Khin Thway (Contributor)
  • Tomohide Tsukahara (Contributor)
  • Jun Nishio (Creator)
  • Elaine T. Huang (Creator)
  • Susan Airhart (Creator)
  • Carol J. Bult (Creator)
  • Regina Gandour-Edwards (Creator)
  • Robert G. Maki (Creator)
  • Robin L. Jones (Creator)
  • Joel E Michalek (Creator)
  • Milan Milovancev (Creator)
  • Souparno Ghosh (Contributor)
  • Ranadip Pal (Contributor)
  • Charles Keller (Creator)
  • Elaine C. Huang Huang (Creator)
  • Robin L. Jones (Creator)

Dataset

Description

Figure S1. Heat map of merged chemical screen, RNA-seq, siRNA, and phosphoproteomics results for GlaxoSmithKline (GSK) Orphan Kinome screen. Due to the large number of compounds and protein targets, only a limited scope of compounds and targets is shown here (for full data, see Additional file 15: Table S1). Bright red indicates high sensitivity values, gradating down to white meaning low sensitivity. Gray indicates no interaction or no available data. Asterisk indicates targets later validated in vivo. (TIF 38030 kb)
Date made available2019
PublisherFigshare

Cite this